Add-on Diuretics in Acute Decompensated Heart Failure

Sponsor
Tanta University
Study ID
NCT07372040
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Acute Decompensated Heart Failure

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • empagliflozin — DRUG
    Empagliflozin may augment the natriuretic and aquaretic actions of loop diuretics in patients with acute decompensated heart failure and it does not typically cause electrolyte disturbances and has been shown to improve outcomes in patients with heart failure
  • Acetazolamide — DRUG
    Acetazolamide can augment the action of loop diuretics in patients with acute decompensated heart failure
  • metolazone — DRUG
    Metolazone can augment the action of loop diuretics in patients with acute decompensated heart failure

Study Details

The aim of this study is to compare the efficacy and safety of empagliflozin, acetazolamide, and metolazone as add-on therapies to loop diuretics in patients with acute decompensated heart failure.

Key Dates

Start date
Feb 1, 2026
Status verified
Jan 2026
Primary completion
Feb 1, 2027
Completion
Feb 1, 2027

Study Design

Enrollment
66 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Empagliflozin group
    will include 22 patients who will receive 10 mg oral empagliflozin administered simultaneously with the first dose of loop diuretics each day for 3 days
  • Active Comparator: Acetazolamide group
    will include 22 patients who will receive 500 mg oral acetazolamide administered simultaneously with the first dose of loop diuretics each day for 3 days
  • Active Comparator: Metolazone group
    will include 22 patients who will receive 5 mg oral metolazone administered simultaneously with the first dose of loop diuretics each day for 3 days

Primary Outcome Measure

The cumulative urine output measured over 3 days [ Time Frame: 3 days ]

Central Contacts

Related Studies